Lee Buyean, Groman Stephanie, London Edythe D, Jentsch James David
Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA 90095-1563, USA.
Neuropsychopharmacology. 2007 Oct;32(10):2125-34. doi: 10.1038/sj.npp.1301337. Epub 2007 Feb 14.
Converging evidence supports a role for mesocorticolimbic dopaminergic systems in a subject's ability to shift behavior in response to changing stimulus-reward contingencies. To characterize the dopaminergic mechanisms involved in this function, we quantified the effects of subtype-specific dopamine (DA) receptor antagonists on acquisition, retention, and reversal of a visual discrimination task in non-human primates (Chlorocebus aethiops sabaeus). We used a modified Wisconsin General Test Apparatus that was equipped with three food boxes, each fitted with a lid bearing a unique visual cue; one of the cues concealed a food reward, whereas the other two concealed an empty box. The monkeys were trained first to acquire a novel discrimination (eg A(+), B(-), C(-)) in a single session, before experiencing either a reversal of the discrimination (eg A(-), B(+), C(-)) or the acquisition of a completely new discrimination (eg D(+), E(-), F(-)), on the following day. Systemic administration of the D(2)/D(3) receptor antagonist raclopride (0.001-0.03 mg/kg) failed to significantly affect the performance of reversal learning when reversal sessions were run without a retention session. But, raclopride (0.03 mg/kg) significantly impaired performance under the reversal condition when reversal sessions were run right after a retention session; however, it did not affect acquisition of a novel visual discrimination. Specifically, raclopride significantly increased the number of reversal errors made before reaching the performance criterion in the reversal, but not in new learning sessions. In contrast, the D(1)/D(5) receptor antagonist SCH 23390 did not significantly modulate acquisition of a novel discrimination or reversal learning at doses (0.001-0.03 mg/kg, i.m.) that did not suppress behavior generally. In addition, none of the drug treatments affected retention of a previously learned discrimination. The results strongly suggest that D(2)/D(3) receptors, but not D(1)/D(5) receptors, selectively mediate reversal learning, without affecting the capacity to learn a new stimulus-reward association. These data support the hypothesis that phasic DA release, acting through D(2)-like receptors, mediates behavioral flexibility.
越来越多的证据支持中脑皮质边缘多巴胺能系统在个体根据不断变化的刺激-奖励意外情况改变行为的能力中发挥作用。为了描述参与该功能的多巴胺能机制,我们量化了亚型特异性多巴胺(DA)受体拮抗剂对非人灵长类动物(埃塞俄比亚绿猴)视觉辨别任务的习得、保持和逆转的影响。我们使用了一种改良的威斯康星通用测试设备,该设备配备了三个食物盒,每个食物盒都配有一个带有独特视觉线索的盖子;其中一个线索隐藏着食物奖励,而另外两个隐藏着空盒子。猴子首先在单个训练阶段被训练习得一种新的辨别(例如A(+),B(-),C(-)),然后在第二天经历辨别逆转(例如A(-),B(+),C(-))或习得全新的辨别(例如D(+),E(-),F(-))。当逆转训练阶段在没有保持训练阶段的情况下进行时,系统性给予D(2)/D(3)受体拮抗剂雷氯必利(0.001 - 0.03 mg/kg)未能显著影响逆转学习的表现。但是,当逆转训练阶段在保持训练阶段之后立即进行时,雷氯必利(0.03 mg/kg)显著损害了逆转条件下的表现;然而,它并不影响新视觉辨别的习得。具体而言,雷氯必利显著增加了在逆转中达到表现标准之前所犯的逆转错误数量,但在新学习训练阶段则没有。相比之下,D(1)/D(5)受体拮抗剂SCH 23390在通常不会抑制行为的剂量(0.001 - 0.03 mg/kg,肌肉注射)下,并未显著调节新辨别的习得或逆转学习。此外,没有一种药物治疗影响先前习得的辨别的保持。结果强烈表明,D(2)/D(3)受体而非D(1)/D(5)受体选择性地介导逆转学习,而不影响学习新的刺激-奖励关联的能力。这些数据支持这样的假设,即通过D(2)样受体起作用的阶段性DA释放介导行为灵活性。